$92.00-2.10 (-2.23%)
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally.
Integer Holdings Corporation in the Healthcare sector is trading at $92.00 with a market capitalization of $3.1B. Wall Street consensus targets $97.56 (9 analysts), implying a +6.0% move over the next 12 months. The stock is currently 26% below its 52-week high of $123.78, remaining 6.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $439.58M↓ | $472.06M↑ | $467.69M↓ | $476.49M↑ | $437.39M |
| Gross Profit | $109.59M↓ | $124.76M↓ | $126.16M↓ | $129.15M↑ | $120.32M |
| Operating Income | $35.47M↓ | $54.55M↓ | $65.90M↑ | $62.90M↑ | $56.13M |
| Net Income | $16.51M↓ | $48.61M↑ | $39.68M↑ | $37.01M↑ | -$22.49M |
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structura...
Why Integer Holdings is on investors’ radar today Investor attention around Integer Holdings (ITGR) has been driven by its recent share performance, with the stock up over the past week, month, past 3 months, and year to date. That move sits against a mixed longer view. The 1 year total return shows a decline, while 3 year and 5 year total returns are positive. This gives you a split picture of how the stock has behaved over different holding periods. See our latest analysis for Integer...
ITGR resets its 2026 outlook after customer forecast changes and slower product ramps, with growth and margin recovery tied to adoption timing.
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 3.8% gain for healthcare stocks has fallen short of the S&P 500’s 10.9% rise.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.